Carriera Lorenzo, Barone Roberto, Ielo Simone, Coppola Angelo
Facoltà di Medicina e Chirurgia, Università Cattolica del Sacro Cuore, Rome, Italy.
UOC Pneumologia, Ospedale San Filippo Neri-ASL Roma 1, Rome, Italy.
Lung India. 2025 Jan 1;42(1):49-52. doi: 10.4103/lungindia.lungindia_337_24. Epub 2024 Dec 24.
The burden of autoimmune diseases is rising worldwide. The expansion of the population of patients eligible for severe asthma biological therapy we are seeing in clinical practice could lead to the simultaneous use of different monoclonal antibodies. We present the case of biological combination therapy with ustekinumab and benralizumab in a patient with ulcerative colitis and severe eosinophilic asthma. The patient, already undergoing biological treatment for colitis, began to suffer from uncontrolled severe asthma. Since benralizumab was administered, the patient has not experienced any exacerbations requiring oral corticosteroids, emergency department visits, or hospital admissions, and the control of asthma symptoms and respiratory function considerably improved. Twelve months after the initiation of the combination, both diseases are well controlled, without any side effects or blood test abnormalities. To our knowledge, this is one of the first reported cases of patients simultaneously receiving a combination of biological therapy for ulcerative colitis and asthma.
自身免疫性疾病在全球范围内的负担正在上升。我们在临床实践中看到，符合重度哮喘生物治疗条件的患者群体不断扩大，这可能导致同时使用不同的单克隆抗体。我们报告了一例使用优特克单抗和贝那利珠单抗联合生物治疗溃疡性结肠炎合并重度嗜酸性粒细胞性哮喘的病例。该患者已在接受针对结肠炎的生物治疗，随后开始出现控制不佳的重度哮喘。自使用贝那利珠单抗以来，患者未经历任何需要口服糖皮质激素、前往急诊科就诊或住院的病情加重情况，哮喘症状和呼吸功能的控制有了显著改善。联合治疗开始十二个月后，两种疾病均得到良好控制，且未出现任何副作用或血液检查异常。据我们所知，这是首批报告的同时接受溃疡性结肠炎和哮喘联合生物治疗的患者病例之一。
